Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Dermatolog Treat ; 27(5): 395-8, 2016 Oct.
Article in English | MEDLINE | ID: mdl-26571044

ABSTRACT

BACKGROUND: Cyclosporine (CysA) is effective for psoriasis in adult patients but little data exist about its efficacy and safety in childhood and adolescence psoriasis. OBJECTIVES: To assess the effectiveness and safety of CysA for childhood and adolescence psoriasis. METHODS: Retrospective analysis of a group of children and adolescents (age < 17 years) with plaque psoriasis treated with CysA at several Italian dermatology clinics. RESULTS: Our study population consisted of 38 patients. The median age at the start of treatment was 12.3 years. Therapy duration varied from one to 36 months. The median maintenance dosage per day was 3.2 mg/kg (range 2-5 mg/kg). Fifteen patients (39,4%) achieved a complete clearance or a good improvement of their psoriasis defined by an improvement from baseline of ≥75% in the psoriasis area and severity index (PASI) at week 16. Eight patients (21.05%) discontinued the treatment due to laboratory anomalies or adverse events. Serious events were not recorded. CONCLUSIONS: In this case series, CysA was effective and well-tolerated treatment in a significant quote of children. CysA, when carefully monitored, may represent a therapeutic alternative to the currently used systemic immunosuppressive agents for severe childhood psoriasis.


Subject(s)
Cyclosporine/therapeutic use , Immunosuppressive Agents/therapeutic use , Psoriasis/drug therapy , Adolescent , Child , Female , Humans , Italy , Male , Retrospective Studies , Treatment Outcome
3.
Clin Exp Dermatol ; 39(7): 801-5, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25156221

ABSTRACT

BACKGROUND: Psoriasis is a highly heritable disease. It has been suggested that psoriasis is preferentially transmitted from fathers. AIM: To evaluate the degree of familial aggregation of psoriasis; to determine the recurrence risk ratio (λR ) of psoriasis in first, second and third degree relatives of patients with psoriasis; and to investigate the transmission patterns of the disease and their relationships with the clinical profiles of patients. METHODS: A cross-sectional study on 640 consecutive, unrelated adult patients with chronic plaque psoriasis was performed. The prevalence of psoriasis in first, second and third degree relatives of the patients was determined, and the λR was calculated under the assumption of a population prevalence of 2%. Age of onset and presence of facial, hand and foot psoriasis were evaluated in probands with paternal vs. maternal transmission. RESULTS: A positive familial history of psoriasis was found in 380 patients (59.37%). Of these, 174 (27.18%) had at least one parent with psoriasis, with a λR of 13.59, while 106 patients (16.56%) had at least one second degree relative with psoriasis, and 34 patients (5.31%) had one third degree relative with psoriasis. No parent-of-origin effect in transmission of psoriasis from affected parent to offspring was observed, and there were no significant differences in the clinical profiles of the disease between patients grouped by transmission pattern of psoriasis. CONCLUSIONS: These results show a high familial recurrence risk of psoriasis, and suggest a balanced parental transmission of the disease.


Subject(s)
Family , Psoriasis/genetics , Adolescent , Adult , Age of Onset , Aged , Aged, 80 and over , Cross-Sectional Studies , Fathers/statistics & numerical data , Female , Genetic Predisposition to Disease , Humans , Male , Middle Aged , Mothers/statistics & numerical data , Odds Ratio , Prevalence , Psoriasis/epidemiology , Recurrence , Young Adult
4.
J Eur Acad Dermatol Venereol ; 25(5): 596-8, 2011 May.
Article in English | MEDLINE | ID: mdl-21492245

ABSTRACT

BACKGROUND: Three aromatase inhibitors, namely anastrozole, letrozole and exemestane, which reduce circulating oestrogen, are used to treat breast cancer patients; the therapeutic use of such aromatase inhibitors is quickly increasing. OBJECTIVE: We intended (i) to review aromatase inhibitor-induced cutaneous adverse effects and (ii) to describe a recently observed case of cutaneous vasculitis triggered by exemestane. PATIENTS/METHODS: The so-far reported literature cases of aromatase inhibitor-induced cutaneous adverse effects were analysed retrospectively. Especially, the clinical case of exemestane-induced cutaneous vasculitis herein reported is unique, because such an observation has not yet been published in the literature. RESULTS: Merely 12 cases of cutaneous adverse reactions induced by aromatase inhibitors, namely erythema nodosum (6), subacute cutaneous lupus erythematosus (1), cutaneous rashes (2), vasculitis (3, including the one described in this study), are reported in the literature. In fact, in the present case, cutaneous vasculitis was strictly related to exemestane. CONCLUSION: As aromatase inhibitors (e.g. exemestane) are increasingly incorporated into the treatment strategy of breast cancer patients, it is important to recognize possible cutaneous adverse effects. Specifically, with regard to cutaneous vasculitis, some patients might progress to severe vasculitis manifestations if the offending drug (e.g. exemestane) is not quickly stopped.


Subject(s)
Androstadienes/adverse effects , Aromatase Inhibitors/adverse effects , Breast Neoplasms/drug therapy , Vasculitis, Leukocytoclastic, Cutaneous/chemically induced , Aged, 80 and over , Female , Humans , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...